Genentech

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Since founding the biotechnology industry nearly 50 years ago, Genentech has remained committed to building a strong and innovative presence in America. In April 2025, we made a $50 billion commitment with our parent company, Roche, to help improve our already significant U.S. footprint. This investment includes new, state-of-the-art R&D and manufacturing facilities, upgrades to existing sites, and the creation of new jobs to support our growing pipeline across our pharmaceutical and diagnostics divisions. Genentech and Roche are doubling our investment in American infrastructure over the next five years to increase our existing footprint and manufacture 20-25 products, including new pipeline medicines and previously-commercialized medicines manufactured abroad.